73
Participants
Start Date
October 31, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
September 30, 2017
ANG1005
ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks
Bevacizumab
For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
UPMC Cancer Center, Pittsburgh
Emily Couric Clinical Cancer Center, Charlottesville
Cleveland Clinic, Cleveland
Northwestern University, Chicago
Univeristy of Texas Health Science Center in San Antonio, San Antonio
University of Washington Medical Center, Seattle
Moores UC San Diego Cancer Center, La Jolla
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Norris Cotton Cancer Center, Lebanon
Seattle Cancer Care Alliance, Seattle
Lead Sponsor
Angiochem Inc
INDUSTRY